All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
This gene is specifically expressed in Schwann cells of the peripheral nervous system and encodes a type I transmembrane glycoprotein that is a major structural protein of the peripheral myelin sheath. The encoded protein contains a large hydrophobic extracellular domain and a smaller basic intracellular domain, which are essential for the formation and stabilization of the multilamellar structure of the compact myelin. Mutations in this gene are associated with autosomal dominant form of Charcot-Marie-Tooth disease type 1 (CMT1B) and other polyneuropathies, such as Dejerine-Sottas syndrome (DSS) and congenital hypomyelinating neuropathy (CHN). A recent study showed that two isoforms are produced from the same mRNA by use of alternative in-frame translation termination codons via a stop codon readthrough mechanism.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-M0227-YC | Anti-MPZ (CBYC-219) h(scFv-41BB-CD3ζ) CAR, pCDCAR1 | Human | CBYC-219 | Rabbit | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-M0228-YC | Anti-MPZ (CBYCD-486) h(scFv-41BB-CD3ζ) CAR, pCDCAR1 | Human | CBYCD-486 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-M0638-YC | Anti-MPZ (CBYC-219) h(scFv-CD28-CD3ζ) CAR, pCDCAR1 | Human | CBYC-219 | Rabbit | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-M0639-YC | Anti-MPZ (CBYCD-486) h(scFv-CD28-CD3ζ) CAR, pCDCAR1 | Human | CBYCD-486 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION